Possible roles of epigenetics in stem cell therapy for Parkinson's disease.


Journal

Epigenomics
ISSN: 1750-192X
Titre abrégé: Epigenomics
Pays: England
ID NLM: 101519720

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 13 5 2020
medline: 27 8 2021
entrez: 13 5 2020
Statut: ppublish

Résumé

Parkinson's disease (PD) is a neurodegenerative disease with loss of dopaminergic neurons. PD has genetic and epigenetic influences that determine specific changes in the brain. Epigenetic changes result in defective methylation of genes leading to differential gene-expression causing PD. This review provides an overview of stem cell transplantations as potential therapies for PD, with a focus on the epigenetic changes, prior or following transplantation. To date, no reports have addressed epigenetic alterations following stem cell transplantation into the PD brain. Given the potential for affecting the efficacy of stem cell therapy, increased attention needs to be given to the epigenetic processes that occur during stem cell culture and transplantation to maximize the therapeutic potential of stem cells to PD.

Identifiants

pubmed: 32396465
doi: 10.2217/epi-2019-0347
doi:

Substances chimiques

Histones 0
RNA, Long Noncoding 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

647-656

Auteurs

Cassandra Thompson (C)

Field Neurosciences Institute laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA.

Paulina Otero (P)

Field Neurosciences Institute laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA.

Bhairavi Srinageshwar (B)

Field Neurosciences Institute laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA.
College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA.

Robert B Petersen (RB)

College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA.

Gary L Dunbar (GL)

Field Neurosciences Institute laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA.
College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Field Neurosciences Institute, St. Mary's of Michigan, Saginaw, MI 48604, USA.

Julien Rossignol (J)

Field Neurosciences Institute laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA.
Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA.
College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH